Compass Therapeutics, Inc. has announced its financial results for the third quarter of 2026, showcasing its ongoing commitment to advancing innovative cancer therapies. The report reveals a significant increase in research and development expenses, reflecting the company's focus on clinical trials and regulatory submissions. With a strong cash position, Compass is poised to continue its efforts in bringing new treatments to market.
Founded in 2014 and headquartered in Boston, Massachusetts, Compass Therapeutics operates in the field of biological products, specifically focusing on oncology. The company is publicly traded on the Nasdaq under the ticker CMPX and has established itself as a clinical-stage biopharmaceutical entity dedicated to developing proprietary antibody-based therapeutics.
In the latest filing, Compass Therapeutics reported a net loss of $27.2 million for the quarter ending September 30, 2026. This marks an increase from the $14.3 million loss reported during the same period in 2025. The company’s research and development expenses surged to $22.0 million, driven primarily by manufacturing costs associated with its lead candidate, tovecimig. General and administrative expenses also rose significantly, totaling $6.8 million for the quarter.
The filing indicates that Compass is actively preparing for a Biologics License Application (BLA) submission for tovecimig, a bispecific antibody targeting DLL4 and VEGF-A, aimed at treating biliary tract cancer (BTC). The company plans to engage further with the FDA to expedite this process. The full results from the COMPANION-002 study of tovecimig have been published in the Journal of Clinical Oncology and presented at the recent ESMO Congress, underscoring the supportive data for the therapy.
In addition to tovecimig, Compass is advancing its pipeline with CTX-8371, a PD-1 x PD-L1 bispecific antibody, which is currently undergoing cohort expansions in patients with triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer. Updates on these studies are expected later this year. Another promising candidate, CTX-10726, has shown a novel mechanism of action and is also in development.
As of September 30, 2026, Compass Therapeutics reported $163 million in cash and marketable securities, which is anticipated to fund operations into 2028. This financial stability positions the company well as it continues to pursue its ambitious clinical development goals.
The filing does not specify what happens next, but the company’s proactive approach suggests that investors and stakeholders can expect further updates on its clinical trials and regulatory engagements in the coming months.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










